Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen Corporation (NASDAQ:RGEN) will report its Q1 2021 financial results on May 4, 2021, with a press release issued before market opening. A conference call will be held at 8:30 a.m. EDT to discuss the results for the three-month period ending March 31, 2021. Callers can join via toll-free numbers for domestic and international participants, with no passcode required. The event will also be available for replay. As a leading life sciences company, Repligen specializes in innovative bioprocessing technologies aimed at enhancing biopharmaceutical manufacturing efficiency.
Repligen Corporation (NASDAQ:RGEN) will present virtually at the KeyBanc Life Science and MedTech Investor Forum on March 23-24, 2021. CEO Tony Hunt will participate in a fireside chat on March 24 at 9:15 a.m. EDT. The discussion will be available via live webcast on the company's Investor Relations website, with a replay accessible for a limited time post-event. Repligen specializes in innovative bioprocessing technologies, serving biopharmaceutical developers and contract manufacturers globally, with headquarters in Waltham, Massachusetts.
Repligen Corporation (NASDAQ:RGEN) will present at the Barclays Global Healthcare Conference from March 9-11, 2021. CFO Jon Snodgres is scheduled for a fireside chat on March 10 at 1:50 p.m. EST. A live webcast of this discussion will be available on the Company’s Investor Relations website and will be accessible for replay afterwards. Repligen specializes in innovative bioprocessing technologies for the biopharmaceutical industry, enhancing drug manufacturing efficiency globally.
Repligen Corporation (NASDAQ:RGEN) reported strong fourth quarter 2020 results with revenues of $108.6 million, a 56% year-over-year increase, driven by sales to COVID vaccine accounts. Total annual revenue reached $366.3 million, up 36% year-over-year. Operating income was $17.4 million, a significant rise, with a GAAP EPS of $0.36. For 2021, Repligen projects revenue between $500-$525 million, reflecting a 37%-43% growth rate.
Repligen Corporation (NASDAQ:RGEN) will present virtually at the 10th Annual SVB Leerink Healthcare Conference from February 22-26, 2021. Tony J. Hunt, the President and CEO, is scheduled to participate in a fireside chat on February 26 at 12:00 p.m. EST. Investors can access a live webcast and replay through the Company’s Investor Relations website. Repligen specializes in bioprocessing technologies that enhance the manufacturing of biological drugs, catering mainly to biopharmaceutical developers globally.
Repligen Corporation (NASDAQ:RGEN) has announced a webcast and conference call to discuss its fourth quarter and full year 2020 financial results, scheduled for February 24, 2021 at 8:30 a.m. EST. The financial report will be released before the market opens. Interested parties can join the call by dialing 844-274-3999 for domestic callers or 412-317-5607 for international callers. Repligen develops innovative bioprocessing technologies for biopharmaceutical manufacturers globally and has facilities in various countries including the U.S., Estonia, Germany, and Sweden.
Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH have announced the commercial launch of the NGL COVID-19 Spike Protein Affinity Resin, designed to enhance the purification process of COVID-19 vaccines. This resin aims to provide a high-purity capture step, reducing processing time and improving yield. The resin meets high-performance standards, including selectivity and dynamic binding capacities. Positive customer feedback has been recorded, with orders for validated resins currently being accepted.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Tony J. Hunt will present on January 13 at 9:10 a.m. EST. A live webcast of the presentation will be available on the Company’s investor relations website and will be accessible for replay afterward.
The company, based in Waltham, Massachusetts, focuses on bioprocessing technologies aimed at improving the efficiency of manufacturing biological drugs, serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ: RGEN) successfully closed its underwritten public offering of 1.725 million shares at $181 each, generating gross proceeds of approximately $312.2 million. After deducting fees, the net proceeds are expected to be about $298 million, intended for working capital and general corporate purposes, including potential investments in complementary businesses. The offering included full exercise of the underwriters’ option for an additional 225,000 shares. The company has no current agreements for acquisitions.
EC Mergers & Acquisitions has announced the successful sale of ARTeSYN BioSolutions to Repligen Corporation for a total transaction value of $200M. This includes $130M in cash and $70M in Repligen common stock. ARTeSYN specializes in single-use solutions for bioprocessing, anticipating $30M in pro forma revenue for 2020. The acquisition is expected to generate approximately $33M-$36M in revenue for Repligen in 2021, enhancing its portfolio in bioprocessing technologies.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
